MBX Biosciences Names CFO
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
Carmel-based biopharmaceutical company MBX Biosciences Inc. has named Richard Bartram chief financial officer. Bartram most recently served as CFO of Michigan-based Esperion Therapeutics Inc. (Nasdaq: ESPR).
MBX develops peptide therapeutics for the the treatment of endocrine disorders.
MBX says at Esperion, a pharmaceutical company that specializes in therapies for patients with elevated LDL cholesterol, Bartram led fundraising efforts resulting in more than $1.2 billion in capital and contributed to several licensing transactions.
“I am delighted to welcome Rick to the MBX leadership team as our CFO and look forward to benefitting from his financial acumen as we strive to advance our innovative pipeline of programs aimed at the development of new medicines for patients with endocrine disorders,” said Kent Hawryluk, chief executive officer of MBX Biosciences. “He has the experience, and the right financial and business skill set to be a driving force in our future growth.”
Bartram also previously served as an assurance manager with London-based PricewaterhouseCoopers LLP from 2005 to 2013.